Wall Street has grown increasingly optimistic ahead of the readout, with analysts pointing to a potential blockbuster ...

New research highlights progress in treating age-related macular degeneration, including late‑stage drug trials, gene therapy strategies, and a wireless retinal prosthesis that restored limited ...

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of ...

Patients with treatment-naive neovascular age-related macular degeneration have positive outcomes with faricimab at 1 year, ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher ...

In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...